Compare EVGN & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVGN | NEUP |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 10.3M |
| IPO Year | N/A | N/A |
| Metric | EVGN | NEUP |
|---|---|---|
| Price | $1.07 | $3.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $21.00 |
| AVG Volume (30 Days) | 47.7K | ★ 103.5K |
| Earning Date | 11-20-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,016,000.00 | ★ $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.19 | N/A |
| 52 Week Low | $0.95 | $2.90 |
| 52 Week High | $2.42 | $21.40 |
| Indicator | EVGN | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 35.97 |
| Support Level | $1.07 | $4.10 |
| Resistance Level | $1.12 | $4.65 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | 0.00 | 0.15 |
| Stochastic Oscillator | 21.05 | 4.02 |
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.